Advances in treating psoriasis in the elderly with small molecule inhibitors

References

• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Grozdev IS, Van Voorhees AS, Gottlieb AB, et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65(3):537–545.
   PubMed Web of Science ®Google Scholar
• Wong JW, Koo JY. The safety of systemic treatments that can be used for geriatric psoriasis patients: a review. Dermatol Res Pract. 2012;2012:367475.
   PubMedGoogle Scholar
• Balato N, Patruno C, Napolitano M, et al. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31(4):233–238.
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, Carretero G, Vanaclocha F, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148(4):463–470.
   PubMed Web of Science ®Google Scholar
• Mak RK, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr. 2009;100(Suppl 2):2–13.
   PubMedGoogle Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol. 2007;33(1–2):45–56.
   PubMed Web of Science ®Google Scholar
• Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology (Oxford). 2005;44:695–696. England.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of Psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961–969.
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Balato N, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016;41(5):564–566.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Umezawa Y, Fukuchi O, et al. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41(11):974–980.
   PubMed Web of Science ®Google Scholar
• Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628–636.
   PubMed Web of Science ®Google Scholar
• Kamangar F, Isip L, Bhutani T, et al. How psoriasis patients perceive, obtain, and use biologic agents: survey from an academic medical center. J Dermatolog Treat. 2013;24(1):13–24.
   PubMed Web of Science ®Google Scholar
• Yiu ZZ, Warren RB. Novel oral therapies for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2016;17(3):191–200.
   PubMed Web of Science ®Google Scholar
• Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol. 2009;183(3):2183–2192.
   PubMed Web of Science ®Google Scholar
• Brahma DK, Wahlang JB, Marak MD, et al. Adverse drug reactions in the elderly. J Pharmacol Pharmacother. 2013;4(2):91–94.
   PubMedGoogle Scholar
• Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–2029.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020.
   PubMed Web of Science ®Google Scholar
• Crowley J, Thaci D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >/=156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310–317.
   PubMed Web of Science ®Google Scholar
• Reich K, Sobell J, Stevens R, et al. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. Presented at: annual congress of the European Academy of Dermatology and Venereology. Amsterdamn, The Netherlands; 2014 Oct 8–12.
   Google Scholar
• Otezla (apremilast) prescribing information. Summit (NJ): Celgene Corporation; 2015.
   Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065–1073.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;2015:906349.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724–1734.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhou S, Wan Y, et al. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. Br J Clin Pharmacol. 2014;78(5):1050–1057.
   PubMed Web of Science ®Google Scholar
• Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318–328.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–570.
   PubMed Web of Science ®Google Scholar
• Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–561.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949–961.
   PubMed Web of Science ®Google Scholar
• Papp KA, Krueger JG, Feldman SR, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841–850.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77(2):302–309.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2015;75(6):1133–1138.
   PubMed Web of Science ®Google Scholar
• Strober B, Buonanno M, Clark JD, et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol. 2013;169(5):992–999.
   PubMed Web of Science ®Google Scholar
• Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129:2299–2302. United States.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–677.
   PubMed Web of Science ®Google Scholar
• Asahina A, Etoh T, Igarashi A, et al. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double‐blind, phase 3 study. J Dermatol. 2016;43(8):869–880.
   PubMed Web of Science ®Google Scholar
• Xeljanz (tofacitinib) prescribing information. New York (NY): Pfizer Labs; 2012.
   Google Scholar
• Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675–2684.
   PubMed Web of Science ®Google Scholar
• Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(11):2924–2937.
   PubMed Web of Science ®Google Scholar
• Chen Z, O’Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res. 2008;41(2):87–102.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol. 2011;131(9):1838–1844.
   PubMed Web of Science ®Google Scholar
• Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67(4):658–664.
   PubMed Web of Science ®Google Scholar
• Punwani N, Burn T, Scherle P, et al. Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor. Br J Dermatol. 2015;173(4):989–997.
   PubMed Web of Science ®Google Scholar
• Ortiz-Ibanez K, Alsina MM, Munoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiliogr. 2013;104(4):304–310.
   PubMedGoogle Scholar
• Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–1276.
   PubMed Web of Science ®Google Scholar
• Papp K, Pariser D, Catlin M, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173(3):767–776.
   PubMed Web of Science ®Google Scholar
• Garg J, Ball G, Cao Y, et al. Pooled analysis of clinical safety data for ASP015K, a novel JAK inhibitor in development for treatment of autoimmune diseases. Ann Rheum Dis. 2013;72:A241–A242.
   PubMed Web of Science ®Google Scholar
• Kamel JG, Yamauchi PS. Managing mild-to-moderate psoriasis in elderly patients: role of topical treatments. Drugs Aging. 2017;34(8):583–588.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–297.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(6):1754–1764.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Balato N, Ayala F, et al. Psoriasis in elderly and non-elderly population: clinical and molecular features. G Ital Dermatol Venereol. 2016;151(6):587–595.
   PubMed Web of Science ®Google Scholar
• Momose M, Asahina A, Hayashi M, et al. Biologic treatments for elderly patients with psoriasis. J Dermatol. 2017;44(9):1020–1023.
   PubMed Web of Science ®Google Scholar
• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180–1185.
   PubMed Web of Science ®Google Scholar
• Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57(6):957–962.
   PubMed Web of Science ®Google Scholar
• Phan C, Sigal ML, Esteve E, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30(1):78–82.
   PubMed Web of Science ®Google Scholar
• Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223:132–142.
   PubMed Web of Science ®Google Scholar
• Sonomoto K, Tanaka Y. Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis. Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(6):443–447.
   PubMedGoogle Scholar
• Kostovic K, Gulin SJ, Mokos ZB, et al. Tofacitinib, an oral Janus Kinase inhibitor: perspectives in dermatology. Curr Med Chem. 2017;24(11):1158–1167.
   PubMed Web of Science ®Google Scholar
• Garber K. Pfizer’s first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nat Biotechnol. 2013;31:3–4. United States.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Betts KA, Sundaram M, et al. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naive patients with psoriasis. J Am Acad Dermatol. 2016;75(4):740–746.
   PubMed Web of Science ®Google Scholar
• D’Souza LS, Payette MJ. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72(4):589–598.
   PubMed Web of Science ®Google Scholar
• Centers for medicare and medicaid services. Center for Medicare and Medicaid Services 2011 Data Compendium, Baltimore, MD; 2011.
   Google Scholar
• Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol. 2015;135(12):2955–2963.
   PubMed Web of Science ®Google Scholar